EXPRESSION OF SOMATOSTATIN RECEPTORS IN CHILDHOOD NEUROBLASTOMA

被引:64
作者
MOERTEL, CL
REUBI, JC
SCHEITHAUER, BS
SCHAID, DJ
KVOLS, LK
机构
[1] UNIV BERN,INST PATHOL,CH-3010 BERN,SWITZERLAND
[2] CHILDRENS HOSP,DEPT HEMATOL ONCOL,ST PAUL,MN
[3] MAYO CLIN & MAYO FDN,DEPT PATHOL,ROCHESTER,MN 55905
[4] MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,DIV BIOSTAT,ROCHESTER,MN 55905
[5] MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905
关键词
CHILDHOOD MALIGNANCY; NEUROBLASTOMA; SOMATOSTATIN RECEPTOR; N-MYC; NEUROENDOCRINE TUMORS; OCTREOTIDE;
D O I
10.1093/ajcp/102.6.752
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Somatostatin receptors are expressed on certain neural crest-derived tumors, including pancreatic islet cell and carcinoid tumors, medullary thyroid carcinomas, pheochromocytomas, and paragangliomas. The authors evaluated the expression of high affinity somatostatin receptors in childhood neuroblastoma using autoradiography techniques with the somatostatin analogue I-125-octreotide or I-125-[Leus, D-Trp(22), Tyr(25)]-SS- 28 as the radioligand. Thirty tumors from 30 children with neuroblastoma were analyzed. Twenty-three of 30 tumors that were tested expressed somatostatin receptors. Correlation of somatostatin receptor expression with survival was statistically significant. The survival of those patients whose tumors expressed somatostatin receptors was of longer duration than that of patients whose tumors did not. This was an independent prognostic factor. Somatostatin receptors were expressed more frequently in tumor tissue from patients with lower stages of disease and in those with no evidence of N-myc amplification. Tumoral somatostatin receptors are expressed in a subgroup of patients with childhood neuroblastoma. Survival analysis in this group of patients indicates that somatostatin receptor expression is a favorable prognostic factor. This finding may have important implications for the therapy of children with this malignancy.
引用
收藏
页码:752 / 756
页数:5
相关论文
共 27 条
[11]  
KAPLAN EL, 1958, J AM STAT ASSOC, V58, P457
[12]   METAIODOBENZYLGUANIDINE (MLBG) IN TREATMENT OF 47 PATIENTS WITH NEUROBLASTOMA - RESULTS OF THE GERMAN NEUROBLASTOMA TRIAL [J].
KLINGEBIEL, T ;
BERTHOLD, F ;
TREUNER, J ;
SCHWABE, D ;
FISCHER, M ;
FEINE, U ;
MAUL, FD ;
WATERS, W ;
WEHINGER, H ;
NIETHAMMER, D .
MEDICAL AND PEDIATRIC ONCOLOGY, 1991, 19 (02) :84-88
[13]   SOMATOSTATIN-RECEPTOR IMAGING IN THE LOCALIZATION OF ENDOCRINE TUMORS [J].
LAMBERTS, SWJ ;
BAKKER, WH ;
REUBI, JC ;
KRENNING, EP .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (18) :1246-1249
[14]  
MANTEL N, 1959, J NATL CANCER I, V22, P719
[15]   BIOCHEMICAL-EVIDENCE FOR SOMATOSTATIN RECEPTORS IN MURINE NEURO-BLASTOMA CLONE N1E-115 [J].
MCKINNEY, M ;
BARRETT, RW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 162 (03) :397-405
[16]   US CHILDHOOD CANCER DEATHS BY CELL TYPE, 1960-68 [J].
MILLER, RW ;
DALAGER, NA .
JOURNAL OF PEDIATRICS, 1974, 85 (05) :664-668
[17]  
MOERTEL CG, 1987, J CLIN ONCOL, V5, P1503
[18]   IMPLICATIONS OF THE UPTAKE OF I-131-RADIOLABELED METAIODOBENZYLGUANIDINE (METAIODOBENZYLGUANIDINE) FOR THE TARGETED RADIOTHERAPY OF NEUROBLASTOMA [J].
ODONOGHUE, JA ;
WHELDON, TE ;
BABICH, JW ;
MOYES, JSE ;
BARRETT, A ;
MELLER, ST .
BRITISH JOURNAL OF RADIOLOGY, 1991, 64 (761) :428-434
[19]  
QUALMAN SJ, 1992, CANCER-AM CANCER SOC, V70, P2005, DOI 10.1002/1097-0142(19921001)70:7<2005::AID-CNCR2820700733>3.0.CO
[20]  
2-H